New Data From NeffyTM (ARS-1) Studies Profiled by AAAAI

According to data ARS Pharmaceuticals originally planned to present at the 2020 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) before its cancellation due to the situation with coronavirus disease 2019 (COVID-19), Neffy 1 mg has the potential to be the first intranasal epinephrine spray product...

ARS Pharmaceuticals Announces the Appointment of Two New Board Members

Expansion of Board of Directors Adds Commercialization and Financial Expertise,  Further Augments Clinical and Scientific Acumen of Medical and Scientific Advisory Board  SAN DIEGO – June 18, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions...